F.D.A. Approves New Eli Lilly Obesity Pill, Foundayo
nytimes.com • • general
Key Points:
- The FDA has approved a new weight-loss pill called orforglipron, branded as Foundayo by Eli Lilly, marking a significant development in obesity treatment.
- Clinical trials showed that patients taking the highest dose of orforglipron lost an average of 12% of their body weight over 72 weeks.
- Orforglipron is the second daily weight-loss pill on the market, comparable in effectiveness to Novo Nordisk's Wegovy, but offers more flexible dosing as it can be taken with or without food at any time.
- The pill's convenience may appeal to patients who prefer to avoid the strict timing required by Wegovy, which must be taken in the morning on an empty stomach.
- The lowest dose of orforglipron will cost $149 without insurance, a price established under a deal announced by the Trump administration.
